Showing 1241-1250 of 2689 results for "".
- FDA Authorizes First Test to Aid in Newborn Screening for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-authorizes-first-test-to-aid-in-newborn-screening-for-duchenne-muscular-dystrophy/2469111/The Food and Drug Administration (FDA) has authorized marketing of the 1st test to aid in newborn screening for Duchenne Muscular Dystrophy (DMD). The test (GSP Neonatal Creatine Kinase—MM; PerkinElmer, Inc., Waltham, MA) works by measuring the concentration of the CK-MM protein, which is p
- Combined Lifestyle Interventions May Offset Alzheimer’s Disease Riskshttps://practicalneurology.com/news/combined-lifestyle-interventions-may-offset-alzheimers-disease-risks/2468957/Research findings reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 suggest that healthy lifestyle choices—including diet, exercise, and cognitive stimulation—may decrease risk of cognitive decline and dementia.
- Clinical Trial of Rimegepant for Trigeminal Neuralgia Enrolls First Participanthttps://practicalneurology.com/news/clinical-trial-of-rimegepant-for-trigeminal-neuralgia-enrolls-first-participant/2468946/The first patient has been enrolled in a double-blind placebo-controlled clinical trial (NCT03941834) to assess rimegepant (Biohaven Pharmaceuticals, New Haven, CT)—a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist—for treatment of trigeminal neuralgia refrac
- OnabotulinumtoxinA Approved for Treatment of Children with Upper Limb Spasticityhttps://practicalneurology.com/news/onabotulinumtoxina-approved-for-treatment-of-children-with-upper-limb-spasticity/2468936/The Food and Drug Administration (FDA) has approved a new indication for onabotulinumtoxinA (Botox; Allergan, Madison, NJ)—treatment of upper limb spasticity in children, age 2 to 17 years. The decision came after a 6-month priority review, which istypically granted to therapies with potent
- Nusinersen Efficacy for Later-Onset Spinal Muscular Atrophy Types II and IIIhttps://practicalneurology.com/news/nusinersen-efficacy-for-later-onset-spinal-muscular-atrophy-types-ii-and-iii/2468883/April 24, 2019—Children with later-onset spinal muscular atrophy (SMA) types II and III treated with nusinersen (Spinraza; Biogen, Cambridge MA) had motor function improvement and disease stabilization over a 3-year period. Of the children with SMA II, 78% (7 of 9) had clinically meaningful
- Multiple Sclerosis Prevalence May Be Twice As High as Previously Thoughthttps://practicalneurology.com/news/multiple-sclerosis-prevalence-may-be-twice-as-high-as-previously-thought/2468830/A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925—more than twice the previous estimate of 400,000 people in
- FDA Recalls Software Used with Surgical Navigation Systemhttps://practicalneurology.com/news/fda-grants-breakthrough-device-designation-for-alzheimers-disease-screening-test/2468857/Medtronic has recalled software used during biopsy procedures due to reports that the products—Synergy Cranial Software and StealthStation S7 Cranial Software—provided incorrect information that could result in serious or life-threatening harm to patients. The FDA has id
- Stem-Cell Transplants Delayed Disease Progression of Multiple Sclerosishttps://practicalneurology.com/news/stem-cell-transplants-delayed-disease-progression-of-multiple-sclerosis/2468861/January 25, 2019—As published in JAMA, interim results of the phase 2 MIST trial (NCT00273364) show that stem-cell treatment resulted in a signific
- FDA Approves Generic Vigabatrin for Complex Partial Seizureshttps://practicalneurology.com/news/fda-approves-generic-vigabatrin-for-complex-partial-seizures/2468865/January 21, 2019—The Food and Drug Administration (FDA) has approved generic vigabatrin 500 mg tablets for adjunctive treatment of patients with complex partial seizures, age 10 years and older, who have not responded adequately to other treatments. “We know there has been
- New Study Will Evaluate Smart Watch Technology for Help in Preventing Strokeshttps://practicalneurology.com/news/new-study-will-evaluate-smart-watch-technology-for-help-in-preventing-strokes/2468864/January 21, 2019—A new study will analyze the impact of a smart watch (Apple, Cupertino, CA) on early detection and diagnosis of atrial fibrillation (AFib) and the potential to prevent stroke. The large-scale research will start later this year in the US and will be a pragmatic, randomized,